Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

SELL
$4.86 - $7.23 $60,137 - $89,464
-12,374 Reduced 46.69%
14,126 $77,000
Q2 2023

Aug 10, 2023

BUY
$5.68 - $10.34 $150,520 - $274,010
26,500 New
26,500 $180,000
Q4 2021

Feb 11, 2022

SELL
$15.51 - $29.31 $269,858 - $509,964
-17,399 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$27.47 - $37.31 $10,960 - $14,886
399 Added 2.35%
17,399 $497,000
Q2 2021

Aug 16, 2021

BUY
$25.45 - $37.64 $432,650 - $639,880
17,000 New
17,000 $575,000
Q3 2020

Nov 16, 2020

SELL
$35.13 - $43.62 $178,952 - $222,200
-5,094 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$23.66 - $49.53 $120,524 - $252,305
5,094 New
5,094 $220,000

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $356M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.